Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.FORMULACIÓN LÍQUIDA ESTABLE QUE CONTIENE EL ANTICUERPO MOR6654B QUE SE UNE AL RECEPTOR DE LA PROTEÍNA BAFFR, LA CUAL ES ESTABILIZADA MEDIANTE SACAROSA O TREHALOSA, HISTIDINA, CITRATO O SUCCINATO, POLISORBATO 20 U 80 Ó HIDROXIPROPIL-B-CICLODEXTRINA Y ARGININA-HCL; DISPOSITIVOS DE SUMINISTRO; JERINGA Y USOS